CAR-T Meeting 2024 | ‘Clinical case discussions’ session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares an insight into a clinical case session held at the CAR-T Meeting 2024. In this session, three clinical cases were presented. The first was a pediatric patient with B-cell acute lymphoblastic leukemia (B-ALL) presenting with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following CAR T-cell infusion. The second was a patient with mantle cell lymphoma (MCL) presenting with recurrent immune effector cell-associated neurotoxicity syndrome (ICANS) and aseptic meningitis following CD19 CAR-T therapy. Dr Popat highlights that this prompted a debate on the use of chemotherapy for the management of ICANS following CAR-T. Finally, the third case dealt with the use of cord-blood derived allogeneic natural killer (NK) cells in conjunction with CAR-NK cells for the treatment of a patient with multiple myeloma (MM). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: GSK
Honoraria: GSK, Janssen, BMS, AbbVie, Roche
Research Funding: GSK
Current Employment: University College London Hospitals NHS Foundation Trust.
